Letrozole Teva Uk

Letrozole, the active ingredient in Letrozole Teva Uk, is an aromatase inhibitor presented as a tablet for oral use. It is indicated for hormone receptor‑positive breast cancer in postmenopausal women, including adjuvant therapy for early‑stage disease. GNH USA supplies Letrozole Teva Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer.

Hormone receptor‑positive breast cancer in postmenopausal women: reduces tumor growth by lowering estrogen levels. Adjuvant treatment of early‑stage breast cancer: decreases risk of disease recurrence after surgery. Metastatic breast cancer in postmenopausal women: slows disease progression and improves survival outcomes.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching or stiffness in joints and muscles. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain in the head. - Dizziness: light‑headed sensation, especially when standing.

Serious or Rare Side Effects: - Severe liver injury: jaundice, dark urine, elevated liver enzymes. - Bone fracture: increased risk of osteoporosis‑related breaks. - Pulmonary embolism: sudden shortness of breath, chest pain. - Anaphylaxis: severe allergic reaction with swelling, rash, difficulty breathing. - Elevated cholesterol: significant rise in blood lipid levels. - QT interval prolongation: potential cardiac rhythm disturbances.

Before initiating Letrozole therapy, several safety considerations should be reviewed.

Pregnancy contraindication: Letrozole is category X and must not be used during pregnancy. Postmenopausal status: indicated only for women who are confirmed postmenopausal. Liver function: monitor hepatic enzymes regularly during treatment. Bone health: assess baseline bone mineral density and consider supplementation. Drug interactions: review concomitant medications for potential interactions. Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may significantly reduce letrozole plasma concentrations. - Tamoxifen: antagonistic effect that can diminish therapeutic benefit. - Warfarin: increased anticoagulant effect leading to higher bleeding risk.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors: may raise letrozole levels, requiring observation. - Statins: potential for increased myopathy; monitor muscle symptoms. - SSRIs (selective serotonin reuptake inhibitors): may exacerbate hot flashes.